Can You Take Vardenafil (Levitra/Staxyn) With Rosuvastatin?

Why This Combination Comes Up Frequently

Men prescribed vardenafil for erectile dysfunction (ED) often carry concurrent cardiovascular risk factors, including hyperlipidemia managed with statins like rosuvastatin. The overlap is predictable: ED prevalence reaches 52% in men aged 40 to 70 in the Massachusetts Male Aging Study cohort [1], and statin use in U.S. Adults over 40 exceeds 28% according to CDC/NCHS data [2].

Shared Patient Demographics

Endothelial dysfunction links both conditions pathophysiologically. Atherosclerotic vascular disease impairs penile blood flow through the same nitric oxide pathway that PDE5 inhibitors target. Rosuvastatin itself may improve endothelial function independent of LDL reduction, as demonstrated in the JUPITER trial (N=17,802) where high-sensitivity CRP decreased 37% alongside a 50% LDL-C reduction [3].

Clinical Relevance of the Question

Patients and prescribers worry about additive hypotension, hepatotoxicity, or muscle toxicity when combining these agents. The pharmacokinetic data, reviewed below, show these concerns are largely unfounded for this specific pairing.

Pharmacokinetic Profiles: No Meaningful Overlap

The core reason this interaction is low-risk lies in divergent metabolic pathways. Vardenafil undergoes extensive hepatic metabolism primarily through CYP3A4, with a minor contribution from CYP2C isoforms [4]. Rosuvastatin, by contrast, is not significantly metabolized by cytochrome P450 enzymes. Approximately 90% of rosuvastatin's clearance depends on hepatic uptake transporters OATP1B1 and OATP1B3, with only about 10% undergoing CYP2C9-mediated biotransformation [5].

CYP3A4: Vardenafil's Rate-Limiting Step

Vardenafil's FDA label explicitly warns against co-administration with potent CYP3A4 inhibitors (ketoconazole, ritonavir, itraconazole) because these agents increase vardenafil AUC by 10-fold or more [4]. Rosuvastatin does not inhibit or induce CYP3A4. It neither accelerates nor slows vardenafil clearance.

OATP Transporters: Rosuvastatin's Bottleneck

Rosuvastatin plasma concentrations rise when OATP1B1/1B3 inhibitors (cyclosporine, certain protease inhibitors) block hepatic uptake [5]. Vardenafil has no documented activity as an OATP inhibitor. Therefore, vardenafil does not alter rosuvastatin exposure.

P-glycoprotein Considerations

Vardenafil is a substrate of P-glycoprotein (P-gp), and rosuvastatin is a substrate of BCRP (breast cancer resistance protein) with minimal P-gp involvement [5]. These transporter profiles do not overlap in a manner that would produce a bidirectional interaction.

Pharmacodynamic Assessment: Blood Pressure and Muscle Safety

Beyond metabolism, two pharmacodynamic concerns deserve evaluation: additive hypotension and combined muscle toxicity.

Blood Pressure Effects

Vardenafil produces modest systemic vasodilation through PDE5 inhibition in vascular smooth muscle. The FDA label reports mean maximal decreases in supine systolic blood pressure of 7 mmHg and diastolic of 8 mmHg at the 20 mg dose [4]. Rosuvastatin has no direct vasodilatory mechanism. The combination does not produce clinically meaningful additive hypotension. This contrasts sharply with the absolute contraindication between PDE5 inhibitors and nitrates, where synergistic cGMP-mediated vasodilation causes dangerous hypotension [6].

Myopathy and Rhabdomyolysis Risk

Statins carry a class-wide risk of myopathy. Rosuvastatin's incidence of myopathy in clinical trials was 0.1% at doses up to 40 mg [5]. Vardenafil does not share this mechanism and does not potentiate statin-induced muscle injury through any known pathway. No case reports in PubMed or the FDA Adverse Event Reporting System (FAERS) link vardenafil co-administration to increased statin myotoxicity.

However, patients already on high-dose rosuvastatin (40 mg) or those with renal impairment (eGFR <30 mL/min/1.73m²) have elevated baseline myopathy risk. Adding any new medication warrants reminding these patients to report muscle symptoms, though vardenafil itself is not the culprit.

Severity Rating and Database Classifications

Major drug interaction databases classify this combination at low severity.

Database Concordance

Lexicomp, Micromedex, and Clinical Pharmacology do not flag a direct vardenafil-rosuvastatin interaction. The FDA prescribing information for vardenafil (revised 2014) lists specific interacting drug classes: CYP3A4 inhibitors, alpha-blockers, antiarrhythmics (Class IA and III), and nitrates [4]. Statins do not appear on this list.

Contrast With Higher-Risk Statin Pairings

For context, simvastatin and lovastatin (both CYP3A4 substrates) carry documented interactions with drugs sharing that metabolic pathway. The FDA limits simvastatin to 10 mg daily with amiodarone and contraindicates it entirely with strong CYP3A4 inhibitors [7]. Rosuvastatin avoids this vulnerability because it bypasses CYP3A4 metabolism almost entirely.

Monitoring Recommendations

No additional monitoring beyond standard-of-care is required for this combination. Standard care includes the following.

Baseline and Periodic Labs

A lipid panel at baseline and 4 to 12 weeks after statin initiation remains appropriate per 2018 AHA/ACC cholesterol guidelines [8]. Hepatic transaminases (ALT) should be checked at baseline. Routine CPK monitoring is not recommended unless the patient reports muscle symptoms.

Symptom-Based Muscle Monitoring

Instruct patients to report unexplained muscle pain, tenderness, or weakness. If symptoms develop, obtain a CPK level. Levels exceeding 10 times the upper limit of normal, combined with symptoms, define statin-associated rhabdomyolysis.

Blood Pressure Awareness

Patients taking vardenafil should understand that co-administration with alpha-blockers or antihypertensives (not rosuvastatin) carries additive hypotension risk. Rosuvastatin does not belong in this cautionary category.

Dose Adjustment Guidance

Neither drug requires dose modification when prescribed together.

Vardenafil Dosing Remains Standard

The starting dose of vardenafil 10 mg taken approximately 60 minutes before sexual activity applies regardless of rosuvastatin use. Dose range: 5 mg to 20 mg. Maximum frequency: once daily [4]. The orally disintegrating tablet (Staxyn) is dosed at 10 mg and is not interchangeable with film-coated tablets due to differing bioavailability.

Rosuvastatin Dosing Remains Standard

Initial dosing of 5 to 20 mg daily with a maximum of 40 mg daily applies per the prescribing information [5]. Asian patients may begin at 5 mg due to higher rosuvastatin exposure observed in pharmacokinetic studies of this population. None of these recommendations change with concurrent vardenafil.

Patient Counseling Points

Clinicians should address several practical points when patients ask about this combination.

Reassurance Without Dismissal

Patients who research their medications online may encounter generic "statin interaction" warnings that conflate all PDE5 inhibitor-statin pairings. Clarify that rosuvastatin's metabolic pathway (OATP/BCRP) does not overlap with vardenafil's (CYP3A4), making this a low-concern combination.

Timing of Administration

No specific timing separation is needed. Vardenafil is taken as needed before intercourse. Rosuvastatin can be taken at any time of day (it has a 19-hour half-life, unlike short-acting statins requiring evening dosing) [5].

When to Seek Medical Attention

Patients should seek emergency evaluation for:

• Erection lasting longer than 4 hours (priapism)
• Sudden vision loss in one or both eyes (non-arteritic anterior ischemic optic neuropathy, reported rarely with PDE5 inhibitors)
• Unexplained severe muscle pain with dark urine (potential rhabdomyolysis, statin-related, not vardenafil-related)

Nitrate Contraindication Reminder

The most dangerous drug interaction for vardenafil users remains concurrent nitrate use. Patients must avoid nitroglycerin (sublingual, patch, spray), isosorbide mononitrate, isosorbide dinitrate, and recreational amyl nitrite ("poppers") [4]. This warning applies regardless of statin status.

Special Populations

Hepatic Impairment

Vardenafil exposure increases in moderate hepatic impairment (Child-Pugh B): the starting dose should be reduced to 5 mg [4]. Rosuvastatin is contraindicated in active liver disease with persistent transaminase elevations exceeding 3 times the upper limit of normal [5]. In patients with compensated hepatic dysfunction, both drugs may be used at reduced doses, but the interaction between them does not change.

Renal Impairment

Vardenafil does not require dose adjustment in mild-to-moderate renal impairment. Rosuvastatin 40 mg is contraindicated in severe renal impairment (eGFR <30), and the 5 mg starting dose applies for moderate impairment [5]. Again, the drug-drug interaction profile is unchanged.

Older Adults

Men over 65 have higher vardenafil plasma concentrations (approximately 52% higher AUC compared to younger men) [4]. A 5 mg starting dose is reasonable. Rosuvastatin pharmacokinetics do not differ significantly by age. The combination remains safe in this demographic with appropriate individual dose selection.

Drugs That Actually Interact With Vardenafil

For clinical completeness, the following agents require caution or contraindication with vardenafil.

Absolute Contraindications

• Nitrates (all forms): severe hypotension risk
• Riociguat (Adempas): synergistic cGMP elevation

Major Interactions Requiring Dose Reduction

• Potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir): reduce vardenafil to 2.5 mg every 72 hours
• Moderate CYP3A4 inhibitors (erythromycin, verapamil, diltiazem): consider 5 mg maximum [4]
• Alpha-blockers (tamsulosin, terazosin, doxazosin): initiate vardenafil at 5 mg, separate dosing by 6 hours with non-selective alpha-blockers

Moderate Interactions

• Class IA antiarrhythmics (quinidine, procainamide): QT prolongation concern
• Class III antiarrhythmics (amiodarone, sotalol): QT prolongation concern

Rosuvastatin does not appear on any of these lists.

Drugs That Actually Interact With Rosuvastatin

Major Interactions

• Cyclosporine: increases rosuvastatin AUC 7-fold via OATP inhibition. Rosuvastatin dose capped at 5 mg [5]
• Gemfibrozil: 2-fold increase in rosuvastatin exposure. Avoid combination or limit rosuvastatin to 10 mg
• Certain protease inhibitors (lopinavir/ritonavir, atazanavir/ritonavir): increase rosuvastatin 2 to 7-fold via OATP/BCRP inhibition [5]

Moderate Interactions

• Warfarin: rosuvastatin may increase INR. Monitor closely during initiation and dose changes
• Antacids (aluminum/magnesium hydroxide): reduce rosuvastatin Cmax by 50%. Administer antacid 2 hours after statin

Vardenafil does not appear on any of these lists either. The drugs occupy separate pharmacological lanes.

The Bottom Line

Vardenafil and rosuvastatin can be prescribed together without dose modification, special timing requirements, or additional monitoring beyond standard statin care. Their metabolic pathways (CYP3A4 vs. OATP1B1/BCRP) do not intersect, and no pharmacodynamic combination produces adverse hemodynamic or musculoskeletal effects. For men managing both ED and dyslipidemia, this is a straightforward co-prescription. The Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism notes that cardiovascular risk factor management should proceed independently of ED pharmacotherapy [9].